Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

9.1%

1 terminated/withdrawn out of 11 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

45%

5 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

4(44.4%)

Phase 4

3(33.3%)

Phase 3

2(22.2%)

9Total

N/A(4)

Phase 4(3)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT04706130Phase 4Completed

Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure

Role: collaborator

NCT04411836Phase 3Completed

Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine

Role: collaborator

NCT04848688Phase 3Completed

Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis

Role: collaborator

NCT03384472Completed

Malaria Genetic Surveillance in Cambodia

Role: collaborator

NCT05117567Not ApplicableUnknown

Reducing Malaria Transmission in Forest-going Mobile and Migrant Populations in Lao PDR and Cambodia

Role: collaborator

NCT02297477Phase 4Unknown

The ASAP Study - Therapeutic Efficacy of Atovaquone-proguanil vs. Artesunate-atovaquone-proguanil in Cambodia

Role: collaborator

NCT01872702Not ApplicableCompleted

Targeted Chemo-elimination (TCE) of Malaria

Role: collaborator

NCT01240603Completed

Plasmodium Falciparum Clearance Rates in Response to Artesunate in Eastern Cambodia

Role: collaborator

NCT02434952Phase 4Completed

Safety and Tolerability of Low Dose Primaquine

Role: collaborator

NCT01624337Not ApplicableTerminated

Malaria Prevention Cambodia

Role: collaborator

NCT01849640Not ApplicableSuspended

Antimalarial Drug Resistance With Assessment of Transmission Blocking Activity

Role: collaborator

All 11 trials loaded